Study to Demonstrate Cognitive Enhancing Effects of BF2.649

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Schizophrenia
Interventions
DRUG

BF2.649

up to 20mg per day

DRUG

Placebo

up to 20mg per day

Trial Locations (2)

75390

The University of Texas Southwestern Medical Center, Dallas

75390-9127

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bioprojet

OTHER

collaborator

Stanley Medical Research Institute

OTHER

lead

University of Texas Southwestern Medical Center

OTHER